Verzenio (abemaciclib) works by blocking two proteins called CDK4 and CDK6 that cancer cells rely on to divide and multiply. It is more potent against these targets than the other two drugs in its class, and unlike its competitors, it’s taken continuously rather than on a cycle with breaks. Verzenio is approved for hormone receptor-positive, HER2-negative breast cancer in both early-stage and metastatic settings.
How Verzenio Stops Cancer Cells From Dividing
Healthy cells move through a tightly regulated cycle when they divide. One critical checkpoint in that cycle is the transition from a resting phase (called G1) into the phase where DNA is copied (called S phase). To pass through this checkpoint, cells need two proteins, CDK4 and CDK6, to team up with partner proteins called cyclins. Together, these pairs flip a molecular switch by disabling a tumor-suppressing protein known as RB1. Once RB1 is turned off, the cell gets the green light to copy its DNA and divide.
In hormone receptor-positive breast cancer, this checkpoint is often hijacked. Cancer cells overactivate CDK4 and CDK6, letting them divide unchecked. Verzenio binds to both CDK4 and CDK6, blocking their activity so RB1 stays active and the cell cycle stalls. The cancer cells get stuck, unable to replicate. Verzenio is more selective for CDK4 than for CDK6, and it inhibits both targets more potently than palbociclib (Ibrance) or ribociclib (Kisqali).
How Verzenio Differs From Other CDK4/6 Inhibitors
All three CDK4/6 inhibitors on the market share the same general mechanism, but Verzenio has a few distinct properties. Palbociclib and ribociclib are taken once daily for 21 days followed by 7 days off in each 28-day cycle. Verzenio is taken twice daily, every day, with no scheduled breaks. This continuous dosing keeps steady drug levels in the body.
Verzenio also crosses the blood-brain barrier, something the other CDK4/6 inhibitors do not do as effectively. In a phase II study published in Clinical Cancer Research, drug concentrations measured directly in brain tumor tissue reached levels 96 times higher than what’s needed to inhibit CDK4 and 19 times higher than what’s needed for CDK6. In cerebrospinal fluid, concentrations exceeded those thresholds by 21-fold and 4.3-fold, respectively. Among patients with brain metastases from HR-positive breast cancer, 38% experienced measurable shrinkage of brain tumors. This makes Verzenio a particularly relevant option when breast cancer has spread to the brain.
Who Is Eligible for Verzenio
Verzenio is FDA-approved for several specific situations, all involving HR-positive, HER2-negative breast cancer:
- Early-stage breast cancer at high risk of recurrence. This means node-positive disease, with high risk defined as either four or more positive lymph nodes, or one to three positive lymph nodes combined with grade 3 tumors or tumors 5 cm or larger. In this setting, Verzenio is paired with hormone therapy (tamoxifen or an aromatase inhibitor) for up to two years after surgery.
- Advanced or metastatic breast cancer, first-line. Combined with an aromatase inhibitor as initial treatment.
- Advanced or metastatic breast cancer after prior hormone therapy. Combined with fulvestrant when the cancer has progressed on previous endocrine treatment.
- Advanced or metastatic breast cancer, on its own. Used as a single agent after both hormone therapy and chemotherapy have been tried in the metastatic setting.
How Well Verzenio Works
In the MONARCH 3 trial, adding Verzenio to an aromatase inhibitor as first-line therapy for advanced breast cancer extended the time before the cancer progressed by a median of 14.3 months compared to the aromatase inhibitor alone. That’s a meaningful delay in disease worsening for patients who otherwise had limited options to improve on standard hormone therapy.
In the MONARCH 2 trial, which studied Verzenio plus fulvestrant in patients whose cancer had progressed on prior hormone therapy, median overall survival was 45.8 months with Verzenio versus 37.3 months with fulvestrant alone. That translates to roughly 8.5 additional months of life, with a hazard ratio of 0.784, meaning a 22% reduction in the risk of death.
Dosing Schedule
The starting dose depends on how Verzenio is being used. In combination with hormone therapy, whether for early-stage or metastatic breast cancer, the standard starting dose is 150 mg twice daily. As a standalone treatment for metastatic disease, it starts at 200 mg twice daily. In both cases, the pills are taken every day without breaks.
If side effects become difficult to manage, your oncologist can reduce the dose in steps. For combination therapy, the first reduction drops to 100 mg twice daily, and the second to 50 mg twice daily. For monotherapy, there’s an additional step available, going from 200 to 150, then 100, then 50 mg. If 50 mg twice daily still isn’t tolerable, the drug is discontinued.
Diarrhea: The Most Common Side Effect
Diarrhea is the most frequent side effect of Verzenio and the one that most distinguishes it from the other CDK4/6 inhibitors, which tend to cause more bone marrow suppression instead. About 43% of patients in clinical trials experienced clinically significant diarrhea (grade 2 or higher). It typically starts fast, with a median onset of just one week after beginning treatment.
The good news is that it’s most intense at the beginning. The highest rates of significant diarrhea occurred during the first treatment cycles, at 32% in one major trial and 21% in another, and then dropped in every subsequent cycle as the body adjusted. Nearly 73% of patients managed their diarrhea with over-the-counter antidiarrheal medication alone. Another 17% needed temporary dose pauses, and about 17% required dose reductions.
If you’re starting Verzenio, expect your care team to recommend beginning antidiarrheal medication at the very first sign of loose stools rather than waiting. If symptoms don’t improve within 24 hours of starting that medication, a dose adjustment is typically the next step. Most patients find the diarrhea becomes manageable or resolves within the first few months of treatment.